Efficacy and Safety of Eplivanserin 5mg/Day on Sleep Maintenance Insomnia: A 6 Week, Multicenter, Randomized, Double -Blind, Placebo-Controlled Study.
Phase of Trial: Phase III
Latest Information Update: 29 Nov 2010
At a glance
- Drugs Eplivanserin (Primary)
- Indications Insomnia
- Focus Registrational; Therapeutic Use
- Acronyms EPOCH
- Sponsors Sanofi
- 16 Jun 2009 Actual initiation date (August 2007), actual patient number (608) added as reported by ClinicalTrials.gov.
- 26 Nov 2007 Status change from in progress to completed
- 15 Nov 2007 Eplivanserin is expected to be launched in 2009.